Quoting Anand Patel, Assistant Professor and Director of the Inpatient Leukemia Service at the University of Chicago, on X/Twitter:
“Our poster (3192) on allogeneic hematopoietic cell transplantation (allo-HCT) in Accelerated Phase of Myeloproliferative Neoplasms/Blast Phase (MPN-AP/BP) in the current era of myeloid therapies at the American Society of Hematology (ASH23).
-65 of 202 patients received allo-HCT.
-Median overall survival 2.3 years from the time of allo-HCT.
-No difference in overall survival based on first-line treatment for MPN-AP/BP or response prior to allo.”
Source: Anand Patel/X